The Cancer Immunology and Immune Modulation (CI&IM) Division of Boehringer Ingelheim (BI) Discovery Research is looking to further enhance its scientific talent base at the BI Research site in Vienna, Austria by appointing an experienced scientist to lead cancer antigen discovery programs.
This individual will join a successful team with a history of discovering and translating cancer targets into novel immunotherapeutic drug candidates.
In addition to directly leading a team of highly skilled laboratory scientists there will be opportunity to lead global project teams that contribute to a sustained and innovative CI&IM portfolio.
Furthermore, there will also be the opportunity to lead collaborations with external academic and biotech partners who support us in the discovery of innovative drug concepts.
As an employee of Boehringer Ingelheim you will actively contribute to the discovery, development and delivery of our products to our patients and customers.
Our global presence provides opportunity for all employees to collaborate internationally, offering visibility and the potential to directly contribute to the companies’ success.
We realize that our strength and competitive advantage lie with our people.
Duties & Responsibilities
For this position we offer an interesting salary considering your expertise and personal competencies as well as your professional experience.
We are obliged by law to state the minimum salary according to the collective agreement, which amounts to € 48,718.04 gross per year (full-
time) for this position. An overpayment is possible. Moreover, we offer our employees a variety of attractive social benefits which will be introduced in the personal interview.
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for.
Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Your application will be reviewed by our recruiting team as well as the respective department. Therefore, we do not state a specific contact person and kindly ask you to use a general salutation in your application.